Dengue vaccine: a valuable asset for the future

Area of Science:

• * Public Health & Tropical Medicine
• * Vaccinology & Virology

Background:

• * Dengue fever is a significant and expanding global public health concern.
• * Increased international travel and climate change contribute to dengue's spread, putting over 2.5 billion people at risk.
• * Despite decades of research, effective dengue prevention remains a challenge.

Purpose of the Study:

• * To review the progress and challenges in dengue vaccine development.
• * To highlight the importance of cost-effective dengue interventions.

Main Methods:

• * Review of historical and current dengue vaccine research, including live-attenuated tetravalent vaccine (CYD-TDV) trials.
• * Analysis of epidemiological data on dengue risk and spread.
• * Consideration of factors complicating vaccine development, such as new serotypes.

Main Results:

• * A live-attenuated tetravalent vaccine (CYD-TDV) has advanced to Phase III efficacy studies.
• * Dengue vaccines are considered a cost-effective strategy for reducing disease burden.
• * The emergence of a fifth dengue serotype presents a new challenge for vaccine efficacy.

Conclusions:

• * Developing a dengue vaccine is critical for mitigating morbidity and mortality.
• * Continued research is needed to address challenges like new serotypes and ensure cost-effective global health solutions.
• * Vaccination represents a promising avenue for controlling the global dengue epidemic.